The University of Southampton
University of Southampton Institutional Repository

Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer

Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer
Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer
BACKGROUND:
Germline BRCA mutations are associated with worse prostate cancer (PCa) outcomes; however, the most appropriate management for mutation carriers has not yet been investigated.

OBJECTIVE:
To evaluate the response of BRCA carriers to conventional treatments for localised PCa by analysing metastasis-free survival (MFS) and cause-specific survival (CSS) following radical prostatectomy (RP) or external-beam radiation therapy (RT).

DESIGN, SETTING, AND PARTICIPANTS:
Tumour features and outcomes of 1302 patients with local/locally advanced PCa (including 67 BRCA mutation carriers) were analysed. RP was undergone by 535 patients (35 BRCA); 767 received RT (32 BRCA). Median follow-up was 64 mo.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:
Median survival and 3-, 5-, and 10-yr survival rates were estimated using the Kaplan-Meier method. Generated survival curves were compared using the log-rank test. Cox regression analyses were used to assess the prognostic value of BRCA mutations.

RESULTS AND LIMITATIONS:
A total of 67 BRCA carriers and 1235 noncarriers were included. At 3, 5, and 10 yr after treatment, 97%, 94%, and 84% of noncarriers and 90%, 72%, and 50% of carriers were free from metastasis (p<0.001). The 3-, 5- and 10-yr CSS rates were significantly better in the noncarrier cohort (99%, 97%, and 85%, respectively) than in carriers (96%, 76%, and 61%, respectively; p<0.001). Multivariate analysis confirmed BRCA mutations as an independent prognostic factor for MFS (hazard ratio [HR]: 2.36; 95% confidence interval [CI], 1.38-4.03; p=0.002) and CSS (HR: 2.17; 95% CI, 1.16-4.07; p=0.016).

CONCLUSIONS:
BRCA carriers had worse outcomes than noncarriers when conventionally treated for local/locally advanced PCa.

PATIENT SUMMARY:
Prostate cancer patients with germline BRCA mutations had worse outcomes than noncarriers when conventionally treated with surgery or radiation therapy.
brca1, brca2, homologous repair, prognostic factor, prostate cancer, prostatectomy, radiotherapy
0302-2838
186-193
Castro, Elena
c7e21bea-2fec-4682-b744-051720d4a6ce
Goh, Chee
3197bcc0-54d2-4855-9662-91c5ddd00467
Leongamornlert, Daniel
d2bcf8a6-c67d-496f-b61a-b31066b07a1d
Saunders, Ed
2c2a1e17-84fa-4e3c-ac27-8e543212f02d
Tymrakiewicz, Malgorzata
fab43482-5a5d-4fb7-af79-d03e26080d77
Dadaev, Tokhir
94476e01-4512-4955-aa99-dca12a490806
Govindasami, Koveela
e565276c-640e-419a-a895-f0ae6837b38c
Guy, Michelle
1c1a79cc-927e-4d2c-ae17-b94064da8aa0
Ellis, Steve
88900da4-3c71-49d0-b2d7-848c08850701
Frost, Debra
38874d28-24d7-47b2-b458-b121539a3ceb
Bancroft, Elizabeth
3b9eca84-7e95-4db7-b68f-43a69d70c3b6
Cole, Trevor
5d7a1e62-1c71-4b07-acdd-652f08f153d4
Tischkowitz, Marc
3c5f5429-fb53-4c80-8a42-6cec37ab67bc
Kennedy, M. John
8f7b041a-5c5e-415a-acc1-83192f80654c
Eason, Jacqueline
537aca11-c033-407a-920e-99b0011bea6c
Brewer, Carole
f497c7f3-050d-4494-aecb-7e6a23101d18
Evans, D. Gareth
314acefb-89fb-4eb7-a0e7-0a6949c9af6c
Davidson, Rosemarie
81692cd9-0a70-4a01-a68f-8eb623f0fbe0
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Porteous, Mary E.
05990ca3-1e88-43d9-983f-d1853589433b
Douglas, Fiona
a35f2e38-4fc4-481e-a212-1e3ae5d5ae0c
Adlard, Julian
3a01574a-8ed1-4286-956c-c9e87fd89521
Donaldson, Alan
8bd5454f-be4c-4b7a-ae31-c602f391920e
Antoniou, Antonis C.
b5275276-df7e-42a4-9a38-6a9516924f0d
Kote-Jarai, Zsofia
c5b0a417-48b3-4cd4-a242-8fad3f4d4bf6
Easton, Douglas F.
2661cf5e-8fc6-4f1d-b27a-e60cac8c8819
Olmos, David
ed104cad-6f27-4f4d-9572-941f61cdb85f
Eeles, Rosalind
ebf4ff74-6a85-49b7-8742-139ddd67ccb4
Castro, Elena
c7e21bea-2fec-4682-b744-051720d4a6ce
Goh, Chee
3197bcc0-54d2-4855-9662-91c5ddd00467
Leongamornlert, Daniel
d2bcf8a6-c67d-496f-b61a-b31066b07a1d
Saunders, Ed
2c2a1e17-84fa-4e3c-ac27-8e543212f02d
Tymrakiewicz, Malgorzata
fab43482-5a5d-4fb7-af79-d03e26080d77
Dadaev, Tokhir
94476e01-4512-4955-aa99-dca12a490806
Govindasami, Koveela
e565276c-640e-419a-a895-f0ae6837b38c
Guy, Michelle
1c1a79cc-927e-4d2c-ae17-b94064da8aa0
Ellis, Steve
88900da4-3c71-49d0-b2d7-848c08850701
Frost, Debra
38874d28-24d7-47b2-b458-b121539a3ceb
Bancroft, Elizabeth
3b9eca84-7e95-4db7-b68f-43a69d70c3b6
Cole, Trevor
5d7a1e62-1c71-4b07-acdd-652f08f153d4
Tischkowitz, Marc
3c5f5429-fb53-4c80-8a42-6cec37ab67bc
Kennedy, M. John
8f7b041a-5c5e-415a-acc1-83192f80654c
Eason, Jacqueline
537aca11-c033-407a-920e-99b0011bea6c
Brewer, Carole
f497c7f3-050d-4494-aecb-7e6a23101d18
Evans, D. Gareth
314acefb-89fb-4eb7-a0e7-0a6949c9af6c
Davidson, Rosemarie
81692cd9-0a70-4a01-a68f-8eb623f0fbe0
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Porteous, Mary E.
05990ca3-1e88-43d9-983f-d1853589433b
Douglas, Fiona
a35f2e38-4fc4-481e-a212-1e3ae5d5ae0c
Adlard, Julian
3a01574a-8ed1-4286-956c-c9e87fd89521
Donaldson, Alan
8bd5454f-be4c-4b7a-ae31-c602f391920e
Antoniou, Antonis C.
b5275276-df7e-42a4-9a38-6a9516924f0d
Kote-Jarai, Zsofia
c5b0a417-48b3-4cd4-a242-8fad3f4d4bf6
Easton, Douglas F.
2661cf5e-8fc6-4f1d-b27a-e60cac8c8819
Olmos, David
ed104cad-6f27-4f4d-9572-941f61cdb85f
Eeles, Rosalind
ebf4ff74-6a85-49b7-8742-139ddd67ccb4

Castro, Elena, Goh, Chee and Leongamornlert, Daniel et al. (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. European Urology, 68 (2), 186-193. (doi:10.1016/j.eururo.2014.10.022). (PMID:25454609)

Record type: Article

Abstract

BACKGROUND:
Germline BRCA mutations are associated with worse prostate cancer (PCa) outcomes; however, the most appropriate management for mutation carriers has not yet been investigated.

OBJECTIVE:
To evaluate the response of BRCA carriers to conventional treatments for localised PCa by analysing metastasis-free survival (MFS) and cause-specific survival (CSS) following radical prostatectomy (RP) or external-beam radiation therapy (RT).

DESIGN, SETTING, AND PARTICIPANTS:
Tumour features and outcomes of 1302 patients with local/locally advanced PCa (including 67 BRCA mutation carriers) were analysed. RP was undergone by 535 patients (35 BRCA); 767 received RT (32 BRCA). Median follow-up was 64 mo.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:
Median survival and 3-, 5-, and 10-yr survival rates were estimated using the Kaplan-Meier method. Generated survival curves were compared using the log-rank test. Cox regression analyses were used to assess the prognostic value of BRCA mutations.

RESULTS AND LIMITATIONS:
A total of 67 BRCA carriers and 1235 noncarriers were included. At 3, 5, and 10 yr after treatment, 97%, 94%, and 84% of noncarriers and 90%, 72%, and 50% of carriers were free from metastasis (p<0.001). The 3-, 5- and 10-yr CSS rates were significantly better in the noncarrier cohort (99%, 97%, and 85%, respectively) than in carriers (96%, 76%, and 61%, respectively; p<0.001). Multivariate analysis confirmed BRCA mutations as an independent prognostic factor for MFS (hazard ratio [HR]: 2.36; 95% confidence interval [CI], 1.38-4.03; p=0.002) and CSS (HR: 2.17; 95% CI, 1.16-4.07; p=0.016).

CONCLUSIONS:
BRCA carriers had worse outcomes than noncarriers when conventionally treated for local/locally advanced PCa.

PATIENT SUMMARY:
Prostate cancer patients with germline BRCA mutations had worse outcomes than noncarriers when conventionally treated with surgery or radiation therapy.

This record has no associated files available for download.

More information

Accepted/In Press date: 15 October 2014
e-pub ahead of print date: 6 November 2014
Published date: August 2015
Keywords: brca1, brca2, homologous repair, prognostic factor, prostate cancer, prostatectomy, radiotherapy
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 382466
URI: http://eprints.soton.ac.uk/id/eprint/382466
ISSN: 0302-2838
PURE UUID: 3046bc6b-a39b-4111-b143-27d882360428
ORCID for Diana Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 05 Oct 2015 12:50
Last modified: 15 Mar 2024 02:40

Export record

Altmetrics

Contributors

Author: Elena Castro
Author: Chee Goh
Author: Daniel Leongamornlert
Author: Ed Saunders
Author: Malgorzata Tymrakiewicz
Author: Tokhir Dadaev
Author: Koveela Govindasami
Author: Michelle Guy
Author: Steve Ellis
Author: Debra Frost
Author: Elizabeth Bancroft
Author: Trevor Cole
Author: Marc Tischkowitz
Author: M. John Kennedy
Author: Jacqueline Eason
Author: Carole Brewer
Author: D. Gareth Evans
Author: Rosemarie Davidson
Author: Diana Eccles ORCID iD
Author: Mary E. Porteous
Author: Fiona Douglas
Author: Julian Adlard
Author: Alan Donaldson
Author: Antonis C. Antoniou
Author: Zsofia Kote-Jarai
Author: Douglas F. Easton
Author: David Olmos
Author: Rosalind Eeles

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×